TrialDiabetes, obesity & metabolism2014

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

T Forst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.